Mark M Goulet

US Patent:

6818658, Nov 16, 2004

Filed:

Feb 3, 2003

Appl. No.:

10/356879

Inventors:

Feroze Ujjainwalla - Scotch Plains NJ
Lin Chu - Scotch Plains NJ
Mark T. Goulet - Westfield NJ
Bonnie Louridas - Somerset NJ
Matthew J. Wyvratt - Mountainside NJ
Daniel Warner - Stoneham MA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 31445

US Classification:

514326, 546193, 546208

Abstract:

Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

US Patent:

7012084, Mar 14, 2006

Filed:

Feb 25, 2002

Appl. No.:

10/468517

Inventors:

Mark T. Goulet - Lexington MA, US
Ravi P. Nargund - East Brunswick NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Thomas F. Walsh - Watchung NJ, US
Daniel Warner - Stoneham MA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/445
C07D 211/06

US Classification:

514330, 514317, 514323, 546208, 546212, 546224, 546226

Abstract:

Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

US Patent:

7015235, Mar 21, 2006

Filed:

Feb 25, 2002

Appl. No.:

10/468515

Inventors:

Mark T. Goulet - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Iyassu K. Sebhat - New York NY, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Thomas F. Walsh - Watchung NJ, US
Daniel Warner - Stoneham MA, US
Zhixiong Ye - Princeton NJ, US
Jonathan R. Young - Kendall Park NJ, US
Raman K. Bakshi - Edison NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/445
C07D 211/06

US Classification:

514330, 514317, 514323, 546208, 546212, 546224, 546226

Abstract:

Certain novel -substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin- receptor (MC-R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

US Patent:

7091216, Aug 15, 2006

Filed:

Aug 1, 2003

Appl. No.:

10/521821

Inventors:

Richard B. Toupence - South Plainfield NJ, US
John S. Debenham - Scotch Plains NJ, US
Mark T. Goulet - Westfield NJ, US
Thomas F. Walsh - Watchung NJ, US
Shrenik K. Shah - Metuchen NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/44
C07D 409/02

US Classification:

514302, 546115

Abstract:

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7423067, Sep 9, 2008

Filed:

Mar 21, 2003

Appl. No.:

10/507864

Inventors:

William K. Hagmann - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Shrenik K. Shah - Metuchen NJ, US
Mark T. Goulet - Westfield NJ, US
James P. Jewell - Jersey City NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/165

US Classification:

514617, 564161, 514357, 546337

Abstract:

Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinsons disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

US Patent:

7622449, Nov 24, 2009

Filed:

Jun 15, 2005

Appl. No.:

11/153192

Inventors:

Mark T. Goulet - Lexington MA, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Anthony Ogawa - Mountainside NJ, US
Derek Von Langen - Scotch Plains NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07H 15/203
C07H 15/26
A61P 9/10
A61P 3/06
A61K 31/7052
C07D 205/08
A61K 31/397

US Classification:

514 25, 536 174, 540200, 514 32

Abstract:

This invention provides cholesterol absorption inhibitors of Formula I:.

US Patent:

7629467, Dec 8, 2009

Filed:

Jul 20, 2004

Appl. No.:

10/565604

Inventors:

Lin Chu - Scotch Plains NJ, US
Mark T. Goulet - Westfield NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Linda Chang - Wayne NJ, US
Richard Frenette - Laval, CA
Yves Girard - Ile-Bizard, CA
Michel Therien - Laval, CA
Dwight Macdonald - L'lle-Bizard, CA
John H. Hutchinson - LaJolla CA, US

Assignee:

Merck & Co., Inc. - Rahway NJ
Merck Frosst Canada Ltd - Quebec

International Classification:

C07D 215/06
C07D 215/12
C07D 215/16
A61K 31/4375

US Classification:

546152, 514311

Abstract:

The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cyto-protective agents.

US Patent:

7700778, Apr 20, 2010

Filed:

Sep 30, 2005

Appl. No.:

11/239770

Inventors:

Mark T. Goulet - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Feroze Ujjainwalla - Scotch Plains NJ, US
Thomas F. Walsh - Watchung NJ, US
Daniel Warner - Stoneham MA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/06
A61K 31/454
A61K 31/451

US Classification:

546208, 546226, 514326, 514330

Abstract:

Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.